Fosfomycin: The Current Status of the Drug

The treatment of patients with prostatitis has been difficult due to the limitations of antibiotics to enter the prostate, fre-quently leading to the need for prolonged regimens. This challenging clinical prob-lem has become even more complicated with the emergence and dissemination of multidrug-resistant (MDR) gram-negative bacterial infections. Among them, Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs), and some-times carbapenemases, have been the cause of various types of infections, including prostatitis, in patients in most parts of the world [1]